Anlotinib

Generic Name
Anlotinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C23H22FN3O3
CAS Number
1058156-90-3
Unique Ingredient Identifier
GKF8S4C432
Background

Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.

Indication

用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。

用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

First Posted Date
2019-05-13
Last Posted Date
2019-07-10
Lead Sponsor
Di Wu
Target Recruit Count
25
Registration Number
NCT03946943
Locations
🇨🇳

First Hospital of Jilin University, Chang chun, Jilin, China

Anlotinib in Advanced Solid Tumors With FGFR Alteration

Not Applicable
Conditions
Advanced Solid Tumor
Interventions
Drug: Anlotinib
First Posted Date
2019-04-29
Last Posted Date
2019-04-29
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
30
Registration Number
NCT03929965
Locations
🇨🇳

Shanghai Changzheng Hospital, Shanghai, Shanghai, China

Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer

Phase 2
Conditions
Ovarian Cancer
First Posted Date
2019-04-23
Last Posted Date
2019-04-23
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
30
Registration Number
NCT03924882
Locations
🇨🇳

The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）

First Posted Date
2019-04-10
Last Posted Date
2019-10-30
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
90
Registration Number
NCT03910127
Locations
🇨🇳

Gansu Province Tumor Hospital, Lanzhou, Gansu, China

🇨🇳

Jilin Cancer Hospital, Changchun, Jilin, China

🇨🇳

Henan Province Tumor Hospital, Luoyan, Henan, China

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

Phase 2
Completed
Conditions
Nasopharyngeal Carcinoma
Interventions
Drug: Anlotinib
First Posted Date
2019-04-08
Last Posted Date
2023-10-25
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
39
Registration Number
NCT03906058
Locations
🇨🇳

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors

First Posted Date
2019-04-01
Last Posted Date
2019-10-30
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
22
Registration Number
NCT03897283
Locations
🇨🇳

Jilin Cancer Hospital, Chang chun, Jilin, China

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

First Posted Date
2019-03-07
Last Posted Date
2024-04-03
Lead Sponsor
Akeso
Target Recruit Count
164
Registration Number
NCT03866980
Locations
🇨🇳

Chinese PLA General Hospital, Beijing, Beijing, China

🇨🇳

Shanghai Chest Hospital, Shanghai, Shanghai, China

Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer

First Posted Date
2019-02-15
Last Posted Date
2019-03-28
Lead Sponsor
Fudan University
Target Recruit Count
70
Registration Number
NCT03841136
Locations
🇨🇳

Cancer hospital Fudan University, Shanghai, Shanghai, China

A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

First Posted Date
2019-01-31
Last Posted Date
2019-10-31
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
60
Registration Number
NCT03825705
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients

Phase 2
Conditions
Sarcoma, Soft Tissue
Interventions
Drug: anlotinib
First Posted Date
2019-01-24
Last Posted Date
2019-07-09
Lead Sponsor
Liaoning Tumor Hospital & Institute
Target Recruit Count
47
Registration Number
NCT03815474
Locations
🇨🇳

Liaoning Province Tumor Hospital, Shenyang, Liaoning, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy